CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the Company has just received the first order from their partner Forbe HealthCare Ltd in Israel.  This first order amounts to DKK 2.6 million, out of the agreed order minimum, of DKK 37,1 million, covering the next 3.5 years. CS MEDICA’S CBD product line will be the first CBD products launched at the Israeli market.

CS MEDICA has just received the first order for the Israeli market from their partner Forbe HealthCare Ltd.  The order includes all CS MEDICA’s medical CBD products, CANNASEN® CBD Arthritis-, Psoriasis-, Protective Nasal-  and Wound gel, Pain Patch and Nasal Spray Night, with a total amount of units of 65.000 and an order value of DKK 2.6 million.  This order is the first of the total minimum order amoounting to DKK 37,1 million, covering the next 3,5 years.

According to the Israeli legislation on CBD, nutraceuticals and cosmetics containing CBD are illegal for the time being, the next 2 years, while medical technical CBD products are excluded in this prohibition. With CS MEDICA’s less than 1PPB THC certificates showing zero traces of THC, the CANNASEN® CBD medical CBD product line are in process to legally be registered and sold in Israel. The launch of CS MEDICA’s medical technical products with CBD will be the first legal CBD products to be launched on the Israeli market.

Lone Henriksen, CEO CS MEDICA comments
“We are very proud to be able to become the first legal CBD brand to enter the Israeli market, notably as Israel is one of the global leaders within the area of CBD and Cannabis research.  We look very much forward to our collaboration with our strong partner in Israel, Forbe HealthCare Ltd., and we are confident that we together will develop a strong success story in the Israeli market.”

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.